Business Wire

All New Bacardi Gift Packs Go 100% Plastic-Free

1.12.2022 15:00:00 EET | Business Wire | Press release

Share

Family-owned Bacardi has extra reason to celebrate this holiday season as it reaches a milestone in its mission to remove 100% of the single-use plastic from its gifting range by the end of 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005320/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

All New Bacardi Gift Packs Are Plastic Free In Time For Holiday Season (Photo: Business Wire)

From this month, ready for the busy festive period, all new gift packs in the Bacardi portfolio – including BACARDÍ® Reserva Ocho rum, GREY GOOSE® vodka, BOMBAY SAPPHIRE® Premier Cru, MARTINI® vermouth, PATRÓN® tequila and DEWAR’S® 12 Year Old Blended Scotch whisky – are now 100% plastic-free.

This significant step will see Bacardi remove almost 275 tons of single-use plastic used annually and has been achieved through innovative new designs that remove plastic or replace it with a sustainably sourced alternative.

As well as using cardboard certified by the Forest Stewardship Council®, the company is also pioneering the use of alternative materials – becoming the first spirits company to use a new biobased, 100% compostable packaging material in its ABERFELDY® 12 Year Old ‘Gold Bar’ gift pack. The sustainable material, made from potato starch and cellulose fibers, replaces plastic vacuum packaging.

“We are committed to being 100% plastic free by 2030 and the removal of plastic from our gift packs is a major milestone on that journey,” said Rodolfo Nervi, Vice President Global Safety, Quality & Sustainability for Bacardi. “For more than 160 years, we have pioneered as a company, and our drive to remove plastic is no exception. We will continue to innovate and explore new sustainable alternative materials to plastic, because it is the right thing to do.”

As part of its ESG – Environmental, Social & Governance – program, Good Spirited, and in line with the United Nations Sustainable Development Goals (SDGs), Bacardi has set a number of goals which it is committed to achieving by 2025. These goals, which are in addition to the company’s commitment to remove all plastic point-of-sales materials by 2023 and to be 100% plastic free by 2030, include:

  • 50% cut in greenhouse gas emissions;
  • 25% cut in water consumption;
  • 100% key raw materials and packaging sourced sustainably;
  • 100% of product packaging to be recyclable;
  • 40% recycled content of product packaging materials;
  • Zero waste to landfill at all production sites.

The new 100% plastic-free gift packs are available in select markets globally throughout the holiday season.

Find out more about Bacardi and its ESG commitments, including its alignment with the United Nations Sustainable Development Goals, at www.bacardilimited.com/good-spirited.

Always drink responsibly.

About Bacardi

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000 people, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media enquiries:
Andrew Carney, Corporate Communications Director, Bacardi, acarney@bacardi.com
Phillippa Williams, Corporate Communications Manager, Bacardi, pholmes@bacardi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye